Toshio Imai

List of Publications by Year
in descending order

26 papers	3,945 citations	430874 18 h-index	552781 26 g-index
26 all docs	26 docs citations	26 times ranked	4201 citing authors

#	Article	IF	Citations
1	Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion. Cell, 1997, 91, 521-530.	28.9	1,272
2	Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture, Firm Adhesion, and Activation under Physiologic Flow. Journal of Experimental Medicine, 1998, 188, 1413-1419.	8.5	641
3	Chemokines in Immunity. Advances in Immunology, 2001, 78, 57-110.	2.2	392
4	Dual Functions of Fractalkine/CX3C Ligand 1 in Trafficking of Perforin+/Granzyme B+ Cytotoxic Effector Lymphocytes That Are Defined by CX3CR1 Expression. Journal of Immunology, 2002, 168, 6173-6180.	0.8	308
5	CX3C-Chemokine, Fractalkine-Enhanced Adhesion of THP-1 Cells to Endothelial Cells Through Integrin-Dependent and -Independent Mechanisms. Journal of Immunology, 2000, 164, 4313-4320.	0.8	199
6	Inhibition of Fractalkine Ameliorates Murine Collagen-Induced Arthritis. Journal of Immunology, 2004, 173, 7010-7016.	0.8	136
7	Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 2878-2883.	6.7	128
8	Role of CX3CL1/Fractalkine in Osteoclast Differentiation and Bone Resorption. Journal of Immunology, 2009, 183, 7825-7831.	0.8	125
9	Fractalkine and vascular injury. Trends in Immunology, 2001, 22, 602-607.	6.8	123
10	Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis and Rheumatism, 2005, 52, 1522-1533.	6.7	117
11	Fractalkine, a CX 3 Câ€chemokine, functions predominantly as an adhesion molecule in monocytic cell line THPâ€1. Immunology and Cell Biology, 2001, 79, 298-302.	2.3	86
12	T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 1392-1401.	6.7	85
13	Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts. Journal of Cell Science, 2013, 126, 1032-45.	2.0	59
14	Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Modern Rheumatology, 2018, 28, 58-65.	1.8	54
15	Inhibition of CX3CL1 (Fractalkine) Improves Experimental Autoimmune Myositis in SJL/J Mice. Journal of Immunology, 2005, 175, 6987-6996.	0.8	53
16	Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway. Inflammation and Regeneration, 2016, 36, 9.	3.7	37
17	Role of Antiâ€Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis. Arthritis and Rheumatology, 2019, 71, 222-231.	5.6	28
18	Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Research and Therapy, 2012, 14, R48.	3.5	25

#	Article	IF	Citations
19	Efficacy and Safety of E6011, an Antiâ€Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Phase II Study. Arthritis and Rheumatology, 2021, 73, 587-595.	5.6	17
20	Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases . ImmunoTargets and Therapy, 2020, Volume 9, 241-253.	5.8	15
21	Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time. International Journal of Molecular Sciences, 2019, 20, 1821.	4.1	12
22	Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the <scp>CX</scp>₃<scp>CL</scp>1/<scp>CX</scp>₃<scp>CR</scp>1 Pathway in Experimental Mouse Models of Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1923-1934.	5.6	11
23	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Modern Rheumatology, 2021, 31, 783-789.	1.8	11
24	Treatment with an Anti-CX3CL1 Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice. Pharmaceuticals, 2021, 14, 474.	3.8	5
25	Monoclonal antibodies specific for podocalyxin expressed on human induced pluripotent stem cells. Biochemical and Biophysical Research Communications, 2020, 532, 647-654.	2.1	3
26	Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112). International Journal of Molecular Sciences, 2021, 22, 4578.	4.1	3